BriaCell Therapeutics Q4 2023 Earnings Report $4.46 -0.61 (-12.03%) As of 02/21/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast BriaCell Therapeutics EPS ResultsActual EPS-$7.50Consensus EPS -$2.70Beat/MissMissed by -$4.80One Year Ago EPSN/ABriaCell Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABriaCell Therapeutics Announcement DetailsQuarterQ4 2023Date12/14/2023TimeAfter Market ClosesConference Call ResourcesBCTX Earnings History BriaCell Therapeutics Earnings HeadlinesBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingFebruary 5, 2025 | globenewswire.comBriaCell Therapeutics Announces Closing of Public OfferingFebruary 5, 2025 | globenewswire.comShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.February 22, 2025 | Brownstone Research (Ad)H.C. Wainwright raises Briacell stock target to $32 on trial successFebruary 4, 2025 | msn.comBriaCell Therapeutics Announces Pricing of Public OfferingFebruary 3, 2025 | globenewswire.comBriaCell announces public offering of common sharesFebruary 3, 2025 | msn.comSee More BriaCell Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BriaCell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BriaCell Therapeutics and other key companies, straight to your email. Email Address About BriaCell TherapeuticsBriaCell Therapeutics (NASDAQ:BCTX), a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.View BriaCell Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
